HemaCell Therapeutics

HemaCell Therapeutics is a UK-based biotechnology company specializing in the development of lab-grown red blood cells for clinical use. A spin-out from the University of Bristol, the company leverages its proprietary Bel-A (Bristol Erythroid Line - Adult) platform to produce immortalized erythroid cell lines. This technology enables the sustainable, large-scale manufacture of red blood cells, specifically targeting patients with rare blood types and those with chronic transfusion needs, such as individuals with sickle cell disease. By creating a consistent supply of high-quality, donor-independent blood cells, HemaCell aims to revolutionize transfusion medicine and address global blood shortages. The company's approach also focuses on reducing the risk of alloimmunization and transfusion-transmitted infections.